AX-2026-041370

Dihexa · 5 mg declared · Wuhan Wansheng Biotechnology Co., Ltd. · lot WWB-2601-C4091

MARGINALPURITY ONLY

Report ID: AX-2026-041370
Compound: Dihexa
Compound class: Neuroactive and cognitive peptides
Supplier: WWB — Wuhan Wansheng Biotechnology Co., Ltd.
Batch / lot: WWB-2601-C4091
Declared label claim: 5mg
Laboratory: Kestrel Bioanalytical
Assay date: 30 May 2026
Submitted: 12 Jun 2026
Quarter: 2026-Q2
Submitter: g.petrov
Sample provenance: Supplier-supplied

Section 1

Results

Measured against the index acceptance specification for the neuroactive and cognitive peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 15 min gradient, 214 nm	99.49	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.51	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — des-hexanoyl (−98 Da)	0.23	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	10.92	%	≤ 12.0	PASS
Counter-ion	no ionisable counter-ion expected	N/A	—	not applicable	NOT TESTED
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.99	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Faint haze, clearing on standing	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	7.68	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 15 min gradient	6.51	min	6.61 ± 0.30 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.92	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	61,177	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Ile]-epimer	0.65	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 15 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 61,177, and skew follows the reported asymmetry factor of 0.92. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.23 % impurity against a 99.49 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Dihexa — main peak	6.51	4,835,522	99.49	—
2	des-hexanoyl (−98 Da)	5.30	11,179	0.23	-98.074
3	free acid (+1 Da)	6.64	9,235	0.19	+0.984
4	[D-Ile]-epimer	6.44	2,430	0.05	0.000
5	hexanoyl bis-adduct (+98 Da)	7.66	1,944	0.04	+98.074
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.49	divergence +0.41 pp vs batch median
Total impurities (% area)	0.10	0.51
Largest single impurity (% area)	0.06	0.23
Water (%)	9.9	10.92
Counter-ion (%)	not stated	N/A
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 2 d) → assay. Submitter did not handle the vial.
Assay date: 30 May 2026
Submitted to the index: 12 Jun 2026
Laboratory: Kestrel Bioanalytical, Melbourne, Australia
Method basis: 15 min gradient · unit-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot WWB-2601-C4091 n=1

This is the only report on this lot. One report is not a batch characterisation.

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Dihexa records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041598	QSC	QSC-2512-D7108	VendorInvestigate	2026-Q2	98.98	6.85	99.4	Laboratory-retained	1	MARGINAL
AX-2026-041597	QSC	QSC-2512-D7108	PeptideMeter	2026-Q2	99.35	6.42	106.3	Supplier-supplied	1	MARGINAL
AX-2026-041602	QSC	QSC-2512-D7108	Nordanalyt	2026-Q2	99.93	5.89	—	Supplier-supplied	0	PASS
AX-2026-041599	QSC	QSC-2512-D7108	Nordanalyt	2026-Q2	99.93	6.03	95.9	Supplier-supplied	0	PASS
AX-2026-041600	QSC	QSC-2512-D7108	Nordanalyt	2026-Q2	99.27	6.20	—	Supplier-supplied	1	MARGINAL
AX-2026-041601	QSC	QSC-2512-D7108	Janoshik	2026-Q2	99.28	6.50	—	Supplier-supplied	2	MARGINAL
AX-2026-042263	Homopeptide	HOMO-2509-M1537	Medutest	2026-Q1	99.58	6.75	—	Supplier-supplied	2	MARGINAL
AX-2025-018683	QYB	QYB-2503-Y6694	Medutest	2025-Q3	99.93	7.57	—	Supplier-supplied	1	MARGINAL

Other recent WWB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041275	Liraglutide	WWB-2607-X2189	Nordanalyt	2026-Q3	99.61	5.03	97.3	Supplier-supplied	0	PASS
AX-2026-041387	BPC-157	WWB-2606-H3906	Janoshik	2026-Q3	98.95	4.64	—	Laboratory-retained	1	MARGINAL
AX-2026-041334	Semaglutide	WWB-2606-N3192	Janoshik	2026-Q3	98.83	5.04	—	Supplier-supplied	1	MARGINAL
AX-2026-041337	Semaglutide	WWB-2606-N3192	Nordanalyt	2026-Q3	98.96	4.81	—	Supplier-supplied	1	MARGINAL
AX-2026-041385	BPC-157	WWB-2606-H3906	Medutest	2026-Q3	99.31	4.31	—	Supplier-supplied	1	MARGINAL
AX-2026-041390	BPC-157	WWB-2606-H3906	Medutest	2026-Q3	99.47	4.84	99.3	Supplier-supplied	1	MARGINAL
AX-2026-041386	BPC-157	WWB-2606-H3906	VendorInvestigate	2026-Q3	99.32	4.88	99.2	Buyer-sourced	1	MARGINAL
AX-2026-041335	Semaglutide	WWB-2606-N3192	Janoshik	2026-Q3	99.55	4.55	100.5	Supplier-supplied	1	MARGINAL